News
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Launch of Public Offering
EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
Evolva Holding SA: Update about earn-out from Danstar
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process
Humana Inc., a leading health and well-being company, today announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians
Sartorius Stedim Biotech SA: Information on Document Availability
Half-year results 2025 of Sartorius Stedim Biotech
Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27
Following an announcement earlier this week, Agilent Technologies Inc. (NYSE: A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial
Humana Simplifies Access to Coverage and Care Information
Humana Inc. [NYSE: HUM] announced today its latest collaboration with healthcare software company Epic, becoming the first health insurer to integrate health plan information directly into the
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product